Home » Author Archive

Image for ProShares Russell US Dividend Growers ETF Plans Dividend of $0.44 (BATS:TMDV)

ProShares Russell US Dividend Growers ETF Plans Dividend of $0.44 (BATS:TMDV)

ProShares Russell US Dividend Growers ETF (BATS:TMDV – Get Free Report) declared a dividend on Friday, December 20th,NASDAQ Dividends reports. Shareholders of record on Monday, December 23rd will be paid a dividend of 0.4359... More of this article »
Image for JPEL Private Equity (LON:JPEL) Share Price Crosses Above 50 Day Moving Average   – What’s Next?

JPEL Private Equity (LON:JPEL) Share Price Crosses Above 50 Day Moving Average – What’s Next?

JPEL Private Equity (LON:JPEL – Get Free Report)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 0.78 ($0.01) and traded as high as GBX 0.78... More of this article »
Image for Westshore Terminals Investment (TSE:WTE) Shares Pass Below 200 Day Moving Average   – What’s Next?

Westshore Terminals Investment (TSE:WTE) Shares Pass Below 200 Day Moving Average – What’s Next?

Westshore Terminals Investment Co. (TSE:WTE – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$23.37 and traded as low as... More of this article »
Image for Claymore CEF GS Connect ETN (NYSEARCA:GSCE)  Shares Down 1.5%   – What’s Next?

Claymore CEF GS Connect ETN (NYSEARCA:GSCE) Shares Down 1.5% – What’s Next?

Claymore CEF GS Connect ETN (NYSEARCA:GSCE – Get Free Report) shares were down 1.5% during trading on Thursday . The stock traded as low as $53.63 and last traded at $53.67. Approximately 7,052 shares changed hands during mid-day... More of this article »
Image for Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial

Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial

On December 20, 2024, Galectin Therapeutics Inc. (NASDAQ: GALT) revealed the top-line results of its NAVIGATE clinical trial in a recent press release. The trial evaluated belapectin in patients with cirrhotic portal hypertension... More of this article »